$993 Million is the total value of Sarissa Capital Management LP's 11 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 18.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ALKS | ALKERMES PLC | $418,252,000 | +13.2% | 14,040,000 | 0.0% | 42.10% | +20.6% | |
| IRWD | IRONWOOD PHARMACEUTICALS INC | $188,977,000 | -8.3% | 16,390,000 | 0.0% | 19.02% | -2.4% | |
| BIIB | BIOGEN INC | $131,133,000 | -3.2% | 643,000 | 0.0% | 13.20% | +3.1% | |
| INVA | INNOVIVA INC | $97,623,000 | -23.7% | 6,614,000 | 0.0% | 9.83% | -18.8% | |
| GILD | Sell | GILEAD SCIENCES INC | $82,943,000 | -10.7% | 1,341,900 | -14.1% | 8.35% | -4.9% |
| AMRN | Sell | AMARIN CORP PLCspons adr new | $35,757,000 | -54.7% | 23,998,000 | -0.0% | 3.60% | -51.8% |
| MRSN | MERSANA THERAPEUTICS INC | $19,863,000 | +15.8% | 4,299,297 | 0.0% | 2.00% | +23.3% | |
| BCRX | BIOCRYST PHARMACEUTICALS INC | $14,715,000 | -34.9% | 1,390,790 | 0.0% | 1.48% | -30.7% | |
| VOR | Sell | VOR BIOPHARMA INC | $3,071,000 | -28.1% | 618,000 | -12.6% | 0.31% | -23.5% |
| PEAR THERAPEUTICS INC | $771,000 | -69.5% | 500,356 | 0.0% | 0.08% | -67.4% | ||
| New | REGULUS THERAPEUTICS INC | $383,000 | – | 185,183 | +100.0% | 0.04% | – | |
| RGLS | Exit | REGULUS THERAPEUTICS INC | $0 | – | -1,851,851 | -100.0% | -0.05% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BIOGEN INC. | 32 | Q3 2023 | 37.1% |
| INNOVIVA INC. | 29 | Q3 2023 | 19.5% |
| IRONWOOD PHARMACEUTICALS INC. | 24 | Q3 2023 | 24.2% |
| ABBVIE INC. | 23 | Q2 2020 | 24.4% |
| MEDICINES CO. | 20 | Q4 2019 | 33.9% |
| MERSANA THERAPEUTICS INC. | 19 | Q3 2023 | 7.9% |
| ALKERMES PLC | 16 | Q3 2023 | 43.7% |
| INTERCEPT PHARMACEUTICALS INC. | 15 | Q2 2021 | 10.7% |
| BIOCRYST PHARMACEUTICALS INC | 14 | Q3 2023 | 7.4% |
| VIVUS INC | 14 | Q1 2017 | 8.8% |
View Sarissa Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Alkermes plc. | August 24, 2023 | 8,323,400 | 5.0% |
| Innoviva, Inc. | May 15, 2023 | 6,904,000 | 10.5% |
| IRONWOOD PHARMACEUTICALS INC | March 01, 2021 | 14,890,000 | 9.3% |
| Iterum Therapeutics plcSold out | February 12, 2021 | 0 | 0.0% |
| BIOCRYST PHARMACEUTICALS INC | January 25, 2021 | 8,844,000 | 5.0% |
| Mersana Therapeutics, Inc. | January 25, 2021 | 3,770,000 | 5.5% |
| MEDICINES CO /DESold out | January 07, 2020 | 0 | 0.0% |
| Regulus Therapeutics Inc. | January 03, 2020 | 7,935,322 | 29.4% |
| NOVELION THERAPEUTICS INC. | November 09, 2018 | 909,296 | 4.6% |
| APRICUS BIOSCIENCES, INC. | September 05, 2018 | 1,152,455 | 4.8% |
View Sarissa Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-03-19 |
| 13F-HR | 2024-02-14 |
| 4 | 2023-12-19 |
| SC 13D/A | 2023-12-05 |
| 13F-HR | 2023-11-14 |
| 4 | 2023-09-19 |
| SC 13D/A | 2023-09-05 |
| SC 13D/A | 2023-08-24 |
| 13F-HR | 2023-08-14 |
| DFAN14A | 2023-06-28 |
View Sarissa Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.